Search Results
May 13, 2026, 03:15 ET AndzonBio2, the ALBORADA Drug Discovery Institute at the University of Cambridge and Cambridge Enterprise Announce a Collaboration to Develop First-in-Class Therapeutics for Neuroinflammation
a central driver of multiple neurodegenerative and neurological conditions such as Parkinson's, Alzheimer's, Amyotropic Lateral Sclerosis and other CNS disorders.
More news about: AndzonBio2
May 12, 2026, 16:00 ET Curis Provides First Quarter 2026 Business Update
inhibitor (BTKi) ibrutinib in the TakeAim Lymphoma Phase 1/2 open-label, single arm expansion trial in patients with Relapsed or Refractory (R/R) Primary CNS Lymphoma (PCNSL) (CA-4948-101, NCT03328078). Patient enrollment in this study is currently ongoing. As a result of discussions with FDA and EMA, the
More news about: Curis, Inc.
May 12, 2026, 08:00 ET 28bio Launches CNS-3D Myelinated Organoids to Predict Therapeutic Efficacy
our CNS-3D Myelinated Organoids has been very positive given the deficiencies of animal models," said Stuart Gibb, Head of Business Development at 28bio. "The model is available as a service today, with assay-ready 96- and 384-replicate formats shipping globally in Q3'26."The launch of CNS-3D Myelinated
More news about: 28bio
May 12, 2026, 04:00 ET Scantox Upgrades DuplexSeq™ Bioinformatics with Cloud-Based Mutagenesis App
generate high-quality, regulator-ready data while keeping timelines and execution aligned across disciplines. Scantox is recognized for deep expertise in CNS pharmacology and Göttingen minipig research, with advanced genetic toxicology and genomic safety capabilities including Big Blue® transgenic rodent assays
More news about: Scantox Group
May 11, 2026, 16:20 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for April 2026
NEW YORK, May 11, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $100.1 billion as of April 30, 2026, an increase of $7.0 billion from assets under management
More news about: Cohen & Steers, Inc.
May 11, 2026, 08:00 ET Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
SPRAVATO® with certain medicine may cause side effects. Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicines. Keep a list of them to show to your healthcare provider and pharmacist
More news about: Johnson & Johnson
May 08, 2026, 17:35 ET Cohen & Steers Announces Changes to Realty Indexes
NEW YORK, May 8, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today pending changes to its Global Realty Majors Portfolio Index (GRM) and International Realty Majors Portfolio Index (IRP), effective as
More news about: Cohen & Steers, Inc.
May 07, 2026, 06:30 ET Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
heavily pre-treated subgroup, including activity in tumors with the ROS1 G2032R resistance mutation and intracranial complete responses for patients with CNS disease. These results indicate that ROS1-positive NSCLC tumors may remain ROS1-dependent beyond treatment with repotrectinib or taletrectinib.Preclinical
More news about: Nuvalent, Inc.
May 06, 2026, 10:07 ET Belay Diagnostics Summit™ Informed Clinical Decisions in 93% of Cases in Large Real-World CNS Study
Belay Summit™ found clinically significant variants in more than half of cytology-negative CNS cancer cases.In a real-world cohort of patients with suspected or confirmed CNS cancer, standard CSF cytology was negative in 86% of specimens. The study, published in Cancers, evaluated
More news about: Belay Diagnostics
May 06, 2026, 08:00 ET Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.About IBTROZIIBTROZI is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, following Priority Review and Breakthrough
More news about: Nuvation Bio Inc.
May 05, 2026, 08:00 ET Apertura Gene Therapy and the TSC Alliance Announce Collaboration to Advance Gene Therapy Programs Designed to Treat Tuberous Sclerosis Complex (TSC)
manufacturing by contract development and manufacturing organizations (CDMOs). TfR1 CapX is a proprietary, second-generation capsid that demonstrates superior CNS delivery compared to Apertura's first-generation capsid, BI-hTFR1. Research on the first-generation BI-hTFR1 capsid was published in
More news about: Apertura Gene Therapy
May 05, 2026, 07:00 ET Corero Network Security Celebrates Michelle Ragusa-McBain Named to 2026 CRN Women of the Channel Power 100
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), leader in real-time DDoS protection and service availability, today announced that Michelle Ragusa-McBain, Vice President of Global
More news about: Corero Network Security
May 04, 2026, 16:10 ET Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Central Nervous System (CNS) cancers. Specifically, the NCCN Guidelines® for CNS Cancers now recommend taletrectinib (IBTROZI) as a systemic therapy option for ROS1+ NSCLC patients with brain metastases.In
More news about: Nuvation Bio Inc.
May 04, 2026, 09:35 ET Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
Transaction Adds Dual BBB Delivery Strategies, Supports Alzheimer's Programs, Combination Therapies, 505(b)(2) Pathways, and CNS Countermeasure ApplicationsSACRAMENTO, Calif., May 4, 2026 /PRNewswire/ -- Lunai Bioworks,
More news about: Lunai Bioworks Inc.
![New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]](https://mma.prnewswire.com/media/1986460/Specialised_Therapeutics_Logo.jpg?w=300){kind=logo}
May 03, 2026, 12:00 ET New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]
specialty therapies where there is an unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. Additional information can be found
More news about: Specialised Therapeutics
Apr 30, 2026, 16:20 ET Cohen & Steers, Inc. Declares Quarterly Dividend
NEW YORK, April 30, 2026 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc. (NYSE: CNS) declared a cash dividend for the second quarter of 2026 in the amount of $0.67 per share of common stock payable on May 21, 2026 to stockholders of
More news about: Cohen & Steers, Inc.
Apr 30, 2026, 10:41 ET Cohen & Steers hernoemt zijn ICBE-strategieën voor preferente aandelen tot hybride kredietstrategieën
SINGAPORE en LONDEN, 30 april 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) heeft vandaag aangekondigd dat het de naam van twee van zijn SICAV-fondsen heeft gewijzigd om beter aan te sluiten bij de marktdefinities van de soorten
More news about: Cohen & Steers, Inc.
Apr 30, 2026, 10:37 ET Cohen & Steers benennt seine „UCITS Preferred Securities Strategies" in „Hybrid Credit Strategies" um
SINGAPUR und LONDON, 30. April 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) gab heute bekannt, dass die Namen von zwei ihrer SICAV-Fonds geändert wurden, um sie besser an die Marktdefinitionen der Wertpapierarten anzupassen,
More news about: Cohen & Steers, Inc.
Apr 30, 2026, 10:33 ET Cohen & Steers rebaptise ses stratégies « UCITS Preferred Securities » en « Hybrid Credit Strategies »
SINGAPOUR et LONDRES, 30 avril 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE : CNS) a annoncé aujourd'hui qu'elle avait changé le nom de deux de ses fonds SICAV afin de mieux refléter les définitions du marché concernant les types de
More news about: Cohen & Steers, Inc.
Apr 30, 2026, 07:00 ET Brenig Therapeutics to Present Hybrid AI Drug Discovery Platform at Keystone Symposia Computational Advances in Drug Discovery
design of highly selective, brain-penetrant small molecules, overcoming the historical tradeoff between potency, selectivity, and central nervous system (CNS) exposure. By combining molecular dynamics–driven structural insights with large-scale AI-enabled property optimization, the platform allows for rapid
More news about: Brenig Therapeutics Inc
Apr 29, 2026, 23:13 ET D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
observed in KRAS G12C inhibitor-pretreated and refractory NSCLC, with an ORR of 32.3% and mPFS of 8.1 months, and significant activity in patients with CNS metastases.SHANGHAI, April 29, 2026 /PRNewswire/ -- D3 Bio Inc.,
More news about: D3 Bio
Apr 29, 2026, 21:00 ET Cohen & Steers Renames UCITS Preferred Securities Strategies as Hybrid Credit Strategies
SINGAPORE and LONDON, April 30, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that it has changed the name of two of its SICAV funds to better align with market definitions of the types of securities in which the
More news about: Cohen & Steers, Inc.
Apr 29, 2026, 18:21 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Apr 29, 2026, 18:07 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Apr 29, 2026, 18:05 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.